Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes - Wijeyeratne, Yanushi Dullewe; Joshi, Rashi; Heptinstall, Stan (Expert review of clinical pharmacology, 2012)
Keywords: acute coronary syndrome; Acute Coronary Syndrome - drug therapy; Acute Coronary Syndrome - prevention & control; Adenosine - adverse effects; Adenosine - analogs & derivatives; Adenosine - pharmacokinetics; Adenosine - pharmacology; antagonists; antiplatelet therapy; Aspirin - adverse effects; Aspirin - pharmacokinetics; Aspirin - pharmacology; Blood Platelets - drug effects; Clinical Trials as Topic; Clopidogrel; cyclopentyl-triazolo-pyrimidine; Drug Therapy, Combination; Humans; Kaplan-Meier Estimate; P2Y; Piperazines - adverse effects; Piperazines - pharmacokinetics; Piperazines - pharmacology; Platelet Aggregation - drug effects; Platelet Aggregation Inhibitors - adverse effects; Platelet Aggregation Inhibitors - pharmacokinetics; Platelet Aggregation Inhibitors - pharmacology; prasugrel; Prasugrel Hydrochloride; Product Surveillance, Postmarketing; Purinergic P2Y Receptor Antagonists - adverse effects; Purinergic P2Y Receptor Antagonists - pharmacokinetics; Purinergic P2Y Receptor Antagonists - pharmacology; thienopyridine; Thiophenes - adverse effects; Thiophenes - pharmacokinetics; Thiophenes - pharmacology; thrombosis; Ticagrelor; Ticlopidine - adverse effects; Ticlopidine - analogs & derivatives; Ticlopidine - pharmacokinetics; Ticlopidine - pharmacology